Highly Sensitized Patients: Miami Transplant Institute Experience.
Adela D MattiazziAlexandra CentenoAlexandra AmadorCasiana Fernandez-BangoCatherine Dillard ScowbyMarian O'RourkeTamieka Hill-MatthieRonak PatelFrances BarriosPhillip RuizLinda ChenJunichiro SaghesimaGaetano CiancioGeorge W BurkeMichael GoldsteinJayanthi ChandarGabriel ContrerasDavid RothWarren KupinGiselle GuerraRodrigo ViannaPublished in: Clinical transplants (2015)
In highly sensitized patients who received desensitization with IVIG, the addition of Rituximab to our standard IS (and/or IVIG and plasmapheresis as per the immunologic risk stratification model) resulted in higher cumulative patient and graft survival.